Literature DB >> 25370513

Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features.

Peggy Auinger, Mary Durbin, Steven Feldon, Mona Garvin, Randy Kardon, John Keltner, Mark J Kupersmith, Patrick Sibony, Kim Plumb, Jui-Kai Wang, John S Werner.   

Abstract

PURPOSE: The accepted method to evaluate and monitor papilledema, Frisén grading, uses an ordinal approach based on descriptive features. Part I showed that spectral-domain optical coherence tomography (SD-OCT) in a clinical trial setting provides reliable measurement of the effects of papilledema on the optic nerve head (ONH) and peripapillary retina, particularly if a 3-D segmentation method is used for analysis.(1) We evaluated how OCT parameters are interrelated and how they correlate with vision and other clinical features in idiopathic intracranial hypertension (IIH) patients.
METHODS: A total of 126 subjects in the IIH Treatment Trial (IIHTT) OCT substudy had Cirrus SD-OCT optic disc and macula scans analyzed by using a 3-D segmentation algorithm to derive retinal nerve fiber layer (RNFL) thickness, total retinal thickness (TRT), retinal ganglion cell layer plus inner plexiform layer (GCL+IPL) thickness, and ONH volume. The SD-OCT parameter values were correlated with high- and low-contrast acuity, perimetric mean deviation, Frisén grading, and IIH features.
RESULTS: At study entry, the average RNFL thickness, TRT, and ONH volume showed significant strong correlations (r ≥ 0.90) with each other. The same OCT parameters showed a strong (r > 0.76) correlation with Frisén grade and a mild (r > 0.24), but significant, correlation with lumbar puncture opening pressure. For all eyes at baseline, neither visual acuity (high or low contrast) nor mean deviation correlated with any OCT measure of swelling or GCL+IPL thickness.
CONCLUSIONS: In newly diagnosed IIH, OCT demonstrated alterations of the peripapillary retina and ONH correlate with Frisén grading of papilledema. At presentation, OCT measures of papilledema, in patients with newly diagnosed IIH and mild vision loss, do not correlate with clinical features or visual dysfunction. (ClinicalTrials.gov number, NCT01003639.). Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  OCT; intracranial hypertension; lumbar puncture; papilledema

Mesh:

Year:  2014        PMID: 25370513      PMCID: PMC4266073          DOI: 10.1167/iovs.14-14961

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Laser scanning tomography of the optic nerve vs CSF opening pressure in idiopathic intracranial hypertension.

Authors:  J G Heckmann; M Weber; A G Jünemann; B Neundörfer; C Y Mardin
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

2.  Automated quantification of volumetric optic disc swelling in papilledema using spectral-domain optical coherence tomography.

Authors:  Jui-Kai Wang; Randy H Kardon; Mark J Kupersmith; Mona K Garvin
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-29       Impact factor: 4.799

3.  Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension.

Authors:  Maren Skau; Hanne Yri; Birgit Sander; Thomas A Gerds; Dan Milea; Rigmor Jensen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-18       Impact factor: 3.117

4.  Detection of mild papilloedema using spectral domain optical coherence tomography.

Authors:  Vardanian Vartin C; A M Nguyen; T Balmitgere; M Bernard; C Tilikete; A Vighetto
Journal:  Br J Ophthalmol       Date:  2011-06-07       Impact factor: 4.638

5.  Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability.

Authors:  Peggy Auinger; Mary Durbin; Steven Feldon; Mona Garvin; Randy Kardon; John Keltner; Mark Kupersmith; Patrick Sibony; Kim Plumb; Jui-Kai Wang; John S Werner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-04       Impact factor: 4.799

6.  Optical coherence tomography of the swollen optic nerve head: deformation of the peripapillary retinal pigment epithelium layer in papilledema.

Authors:  Mark J Kupersmith; Patrick Sibony; Gary Mandel; Mary Durbin; Randy H Kardon
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-22       Impact factor: 4.799

Review 7.  Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection.

Authors:  Reiko E Sakai; Daniel J Feller; Kristin M Galetta; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2011-12       Impact factor: 3.042

8.  Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study.

Authors:  Maren Skau; Birgit Sander; Dan Milea; Rigmor Jensen
Journal:  J Neurol       Date:  2010-09-19       Impact factor: 4.849

9.  OCT for optic disc evaluation in idiopathic intracranial hypertension.

Authors:  Maren Skau; Dan Milea; Birgit Sander; Marianne Wegener; Rigmor Jensen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-15       Impact factor: 3.117

10.  The idiopathic intracranial hypertension treatment trial: design considerations and methods.

Authors:  Deborah I Friedman; Michael P McDermott; Karl Kieburtz; Mark Kupersmith; Ann Stoutenburg; John L Keltner; Steven E Feldon; Eleanor Schron; James J Corbett; Michael Wall
Journal:  J Neuroophthalmol       Date:  2014-06       Impact factor: 3.042

View more
  27 in total

Review 1.  Current concepts and strategies in the diagnosis and management of idiopathic intracranial hypertension in adults.

Authors:  Jane W Chan
Journal:  J Neurol       Date:  2017-01-31       Impact factor: 4.849

2.  The Effect of Treatment of Idiopathic Intracranial Hypertension on Prevalence of Retinal and Choroidal Folds.

Authors:  Mark J Kupersmith; Patrick A Sibony; Steven E Feldon; Jui-Kai Wang; Mona Garvin; Randy Kardon
Journal:  Am J Ophthalmol       Date:  2016-12-28       Impact factor: 5.258

3.  Photographic Reading Center of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): Methods and Baseline Results.

Authors:  William S Fischer; Michael Wall; Michael P McDermott; Mark J Kupersmith; Steven E Feldon
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

4.  Diffusion tensor imaging of the optic disc in idiopathic intracranial hypertension?

Authors:  Halil Onder
Journal:  Neuroradiology       Date:  2018-11-28       Impact factor: 2.804

Review 5.  Noninvasive methods of detecting increased intracranial pressure.

Authors:  Wen Xu; Patrick Gerety; Tomas Aleman; Jordan Swanson; Jesse Taylor
Journal:  Childs Nerv Syst       Date:  2016-06-28       Impact factor: 1.475

6.  Use of A-scan Ultrasound and Optical Coherence Tomography to Differentiate Papilledema From Pseudopapilledema.

Authors:  Roberto Saenz; Han Cheng; Thomas C Prager; Laura J Frishman; Rosa A Tang
Journal:  Optom Vis Sci       Date:  2017-12       Impact factor: 1.973

Review 7.  Update on Idiopathic Intracranial Hypertension.

Authors:  Michael Wall
Journal:  Neurol Clin       Date:  2017-02       Impact factor: 3.806

Review 8.  Update on Idiopathic Intracranial Hypertension.

Authors:  Sivashakthi Kanagalingam; Prem S Subramanian
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

9.  Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension.

Authors:  Vivek Vijay; Susan P Mollan; James L Mitchell; Edward Bilton; Zerin Alimajstorovic; Keira A Markey; Anthony Fong; Jessica K Walker; Hannah S Lyons; Andreas Yiangou; Georgios Tsermoulas; Kristian Brock; Alexandra J Sinclair
Journal:  JAMA Ophthalmol       Date:  2020-12-01       Impact factor: 7.389

10.  Retinal and Choroidal Folds in Papilledema.

Authors:  Patrick A Sibony; Mark J Kupersmith; Steven E Feldon; Jui-Kai Wang; Mona Garvin
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.